Validation of <sup>111</sup>In-Exendin SPECT for the Determination of the β-Cell Mass in BioBreeding Diabetes-Prone Rats.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30045920.
- Also identified by DOI 10.2337/db17-1312.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The changes in β-cell mass (BCM) during the development and progression of diabetes could potentially be measured by radionuclide imaging using radiolabeled exendin. In this study, we investigated the potential of <sup>111</sup>In-diethylenetriaminepentaacetic acid-exendin-3 (<sup>111</sup>In-exendin) in a rat model that closely mimics the development of type 1 diabetes (T1D) in humans: BioBreeding diabetes-prone (BBDP) rats. BBDP rats of 4-18 weeks of age were injected intravenously with <sup>111</sup>In-exendin, and single-photon emission computed tomography (SPECT) images were acquired. The accumulation of the radiotracer was measured as well as the BCM and grade of insulitis by histology. <sup>111</sup>In-exendin accumulated specifically in the islets, resulting in a linear correlation with the BCM (%) (Pearson <i>r</i> = 0.89, <i>P</i> < 0.0001, and <i>r</i> = 0.64 for SPECT). Insulitis did not have an influence on this correlation. These results indicate that <sup>111</sup>In-exendin is a promising tracer to determine the BCM during the development of T1D, irrespective of the degree of insulitis.
Medical subject headings
- Indium Radioisotopes
- Insulin-Secreting Cells
- Peptides